Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 24Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Neuroblastoma 4Neoplasms 4Lymphoma 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Select Advanced Solid Tumors × Interleukin-2 × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡